Avaleht › Haavandiline koliit › Virginia
Haavandiline koliit kliinilised uuringud osariigis Virginia
14 uuringut haiguse Haavandiline koliit jaoks otsivad osalejaid osariigis Virginia.
Linnad osariigis Virginia
Ametlik uuringutekst (inglise keeles)
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
- University of Virginia Health System ( Site 0291), Charlottesville
VärbamineFaas 3
Kõik vanused · Kõik sood · Uuendatud 2. okt 2026 · NCT06651281Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Emeritas Research Group /ID# 284388, Lansdowne Town Center
- GI Alliance - Richmond /ID# 284244, Richmond
VärbamineFaas 2
Vanused 18–75 · Kõik sood · Uuendatud 2. okt 2026 · NCT07697456A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Gastroenterology Consultants of Southwest Virginia., Roanoke
VärbamineFaas 4
Vanused 18–80 · Kõik sood · Uuendatud 30. sept 2026 · NCT06581328Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
- Xencor Investigative Site, Richmond
VärbamineFaas 1/2Terved vabatahtlikud oodatud
Vanused 18–75 · Kõik sood · Uuendatud 29. sept 2026 · NCT06619990A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis
- Site US-013, Richmond
VärbamineFaas 2
Vanused 18–75 · Kõik sood · Uuendatud 29. sept 2026 · NCT07845487A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
- Gastroenterology Associates of Tidewater, Chesapeake
- Blue Ridge Medical Research, Lynchburg
VärbamineFaas 3
Vanused 12 ja vanemad · Kõik sood · Uuendatud 25. sept 2026 · NCT07196748Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Gastroenterology Consultants of Southwest Virginia, Roanoke
VärbamineFaas 3
Vanused 18–70 · Kõik sood · Uuendatud 24. sept 2026 · NCT06937086Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- VCU Massey Comprehensive Cancer Center, Richmond
VärbamineFaas 1
Vanused 18 ja vanemad · Kõik sood · Uuendatud 23. sept 2026 · NCT03816345LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
- Clinical Research Partners, LLC, Richmond
- GI Alliance - Richmond, Richmond
- Carilion Clinic, Roanoke
VärbamineFaas 2
Vanused 18–80 · Kõik sood · Uuendatud 22. sept 2026 · NCT07186101A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
- Pediatric Specialists of Virginia, Fairfax
VärbamineFaas 3
Vanused 2–19 · Kõik sood · Uuendatud 22. sept 2026 · NCT04844606LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
- Eximia Research-VA, LLC, Norfolk
VärbamineFaas 2
Vanused 18–80 · Kõik sood · Uuendatud 22. sept 2026 · NCT07415044An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
- Blue Ridge Medical Research - Site Number: 8400020, Lynchburg
- Clinical Research Partners - Site Number: 8400080, Richmond
VärbamineFaas 3
Vanused 16–80 · Kõik sood · Uuendatud 20. aug 2026 · NCT07184996A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- Carilion Children's Tanglewood Center, Roanoke
VärbamineFaas 3
Vanused 2 ja vanemad · Kõik sood · Uuendatud 7. mai 2026 · NCT05442567Ketogenic and Carnivore (Lion) Diets for Inflammatory Bowel Disease and Rheumatoid Arthritis
- Resilient Roots: Functional Medicine, Charlottesville
Värbamine
Vanused 18–64 · Kõik sood · Uuendatud 16. apr 2026 · NCT07524244Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.